A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer

Content Provider	Semantic Scholar
Author	Ikeda, Takaya Fukuda, Minoru Nakamura, Yoichi Kinoshita, Akitoshi Senju, Hiroaki Nakano, Hirofumi Kitazaki, Takeshi Ogawara, Daiki Taniguchi, Hirokazu Motoshima, Kohei Yamaguchi, Hiroyuki Nakatomi, Katsumi Shimada, Midori Nagashima, Seiji Tsukamoto, Kazuhiro Kohno, Shigeru
Copyright Year	2014
Abstract	BackgroundAmrubicin is active in the treatment of extensive-disease small cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less non-hematological toxicity.PurposeThe purpose of this study was to determine the efficacy and toxicity of amrubicin and carboplatin combination chemotherapy for previously untreated patients with ED-SCLC.Patients and methodsEligibility criteria were chemotherapy-naïve ED-SCLC patients, performance status 0–1, age ≤75, and adequate hematological, hepatic and renal function. Based on the phase I study, the patients received amrubicin 35 mg/m2 i.v. infusion on days 1, 2, and 3, and carboplatin AUC 5 i.v. infusion on day 1. Four cycles of chemotherapy were repeated every 3 weeks.ResultsThirty-five patients were enrolled, and 34 patients were eligible and assessable for response, toxicity, and survival. Patients’ characteristics were as follows: male/female = 26/8; performance status 0/1 = 4/30; median age (range) = 64 (41–75); stage IV = 34. Evaluation of responses was 6 complete response, 21 partial response, and 7 stable disease (response rate 79.4 %, 95 % CI 63.6–88.5 %). Grade 3 and 4 leukopenia, neutropenia, and thrombocytopenia occurred in 59, 82, and 26 %, respectively. There were no treatment-related deaths or pneumonitis. Three patients experienced hypotension as an amrubicin infusion reaction. The median progression-free survival time was 6.5 months. The median overall survival time and 1-, 2-, and 3-year survival rates were 15.6 months, and 63, 28, and 7 %, respectively.ConclusionsAmrubicin and carboplatin were effective and tolerable as chemotherapy for previously untreated patients with ED-SCLC. Further investigation of amrubicin and carboplatin is warranted.
Starting Page	497
Ending Page	502
Page Count	6
File Format	PDF HTM / HTML
DOI	10.1007/s00280-014-2527-4
PubMed reference number	25034978
Journal	Medline
Volume Number	74
Alternate Webpage(s)	http://naosite.lb.nagasaki-u.ac.jp/dspace/bitstream/10069/34902/1/CCP74_497.pdf
Alternate Webpage(s)	https://doi.org/10.1007/s00280-014-2527-4
Journal	Cancer Chemotherapy and Pharmacology
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article